Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Eagle Pharmaceuticals (EGRX) PT Raised to $84 at RBC Capital
August 8, 2018 8:32 AM EDTRBC Capital raised its price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $84.00 (from $74.00) while maintaining a Outperform rating.
... MoreEagle Pharmaceuticals (EGRX) Tops Q2 EPS by 15c, Revenues Beat
August 7, 2018 6:52 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.95, $0.15 better than the analyst estimate of $0.80. Revenue for the quarter came in at $59.3 million versus the consensus estimate of $51.23 million.
Total revenue for the second quarter of 2018 was $59.3 million, compared to $50.1 million in the second quarter of 2017;Eagle launched bendamustine hydrochloride 500ml solution (Big Bag) on May 15, 2018 and Big Bag product sales were $8.1 million in the second quarter of 2018;Q2 2018 Ryanodex product sales were $7.2 million, up 38% compared to Q2 2017;Q2 2018 net income was $2.7 million, or $0.18 per basic and $0.17 per diluted... More